NEW YORK (TheStreet) -- GW Pharmaceuticals
(GWPH) shares are spiking, up 8.1% to $103.98, on Monday after analysts at Piper Jaffray
(PJC - Get Report) drastically increased its price target to $147 from $97.
The improved valuation stems from an analyst's evaluation of the U.K. based pharmaceutical company's cannabinoid based epilepsy treatment, Epidolex.
Analysts Dr. Joshua Schimmer believes that the drug is a "highly attractive" treatment for children suffering from Dravet Syndrome, as children treated with it have fewer seizures and can take lower doses of other medicines.
Must Read: Warren Buffett's 25 Favorite Stocks
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts